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Abstract
This article aims to provide an overview of drug discovery with a focus on application within 
dermatology.  The term “drug” can be used to describe a wide variety of agents, including small 
molecules, cell therapies and antibodies, which may be dosed intravenously, orally, topically or by 
other routes of administration.  We summarize the economics and risks involved in drug discovery.  
Understanding the needs of patients and clinicians through use of a target product profile (TPP) prior
to initiating drug discovery can reduce time and effort spent developing a poor or unneeded drug.  
For small molecule drug discovery a chemical starting point is then required. We present four options
for finding a chemical starting point for drug discovery projects: screening libraries of compounds or 
modifying, reformulating or re-positioning a known drug.  Examples of each technique’s use in 
dermatology are provided.  We also describe the subsequent steps involved in discovery of a new 
drug.  To help interested readers, we provide information on how to engage with academic drug 
discovery centres or industrial partners.
Key points
 Drug Discovery is expensive, time consuming and risky.  To discover a drug, it is estimated 
that on average 24 projects must be started, at a total cost of around $1.8 billion over 10-15 
years. 
 Drugs may be small molecules or biological therapies and may be designed for application 
through a range of routes of administration.
 Before starting a project the acceptable success criteria are defined in a target product 
profile (TPP).
 The process of discovering a drug can be broken down into a series of stages.  Hit 
identification, hit to lead and lead optimisation describe progress towards inventing a 
potential drug (discovery); pre-clinical development, Phase I-III clinical trials and registration 
are stages of drug evaluation and approval (development).
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 There are a number of approaches to the discovery of a small molecule drug, each with their 
advantages: screening, fast-follower, repositioning and re-formulation.
Introduction
Drug discovery is a complex, slow, risky and expensive process, Figure 1.  It is estimated that it takes, 
on average, around 10-15 years and $1.8 billion of investment for each new drug launched (Paul et 
al., 2010).  Only around 1 in 25 projects successfully deliver a drug, with many failures occurring 
towards the end of the process in expensive Phase 2 and Phase 3 clinical trials.  As a result, drug 
discovery is dominated by the cost of failure (Paul et al., 2010), Figure 1.  
The pharmaceutical industry delivered many new valuable therapies for dermatology between the 
1950s and 1990s (Benedek, 2011).  Dermatology then experienced a hiatus, with most therapeutic 
innovation focusing on the optimisation of dosage or delivery vehicles, rather than the discovery of 
new medicines (Humphries et al., 2016).  Today however, dermatology is attracting record levels of 
investment, with 28 new approvals in the last 5 years for drugs treating skin disease (CenterWatch, 
2019), Table 1.
Types of drugs for dermatology 
Discovering a drug for dermatology is in most ways identical to any other indication.  A drug treating 
a dermatological condition may be an oral, topical or injectable low molecular weight small molecule
(usually 200-600 Daltons).  Alternatively, it may be a biological agent such as an antibody, silencing 
RNA, peptide replacement or cell therapy.  Each type of drug has advantages and disadvantages that 
must be considered during development.  Similarly, the discovery and development of different 
classes of drug will require the input of specialist experts in drug design, manufacture and clinical 
development.  
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The complexity of drug development means that no one person can discover a drug.  Interested 
parties are therefore encouraged to seek out collaborators or partners who can complement their 
skill sets. 
Centres of excellence 
In the last 10 years there has been a large increase in the number of not for profit drug discovery 
facilities.  The Academic Drug Discovery Consortium lists 149 centres worldwide (Academic Drug 
Discovery Consortium, 2018).  These centres typically work on a wide range of targets and diseases, 
although some focus on specific therapeutic areas.  The centres can offer a range of capabilities, 
allowing them to collaboratively run early to mid-stage projects.  
There are however few centres that are capable of progressing projects through all stages of a drug 
discovery process, although these do exist and are increasing in number (Frye et al., 2011; Tralau-
Stewart et al., 2014).  
Most pharmaceutical companies describe on their web sites how they engage with academic or 
clinical partners.  Examples of dermatology-focused companies include Almirall, LEO Pharma, 
Galderma-Nestlé Skin Health, Pierre Fabre, GSK-Stiefel and Maruho Co. Ltd.  This list is not exhaustive
and there are many other companies (small and large) with an interest in dermatology. 
Initiating a new drug discovery project: defining success
Before commencing drug discovery, a project must first carefully consider what patient and 
healthcare professionals need in a new product.  This information is usually gathered in the form of a
Target Product Profile (TPP), Table 2.  The TPP is a strategic document that defines the required 
development outcome.  Project teams work back from the TPP to define the success criteria for each 
stage of the project, Figure 1.  TPPs are rarely published by companies as they are considered to be 
commercially sensitive.  However, some not-for-profit organisations publish their TPPs, which can 
serve as useful templates (Drugs for neglected diseases initiative 2018).  
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A TPP consists of a series of questions, which focus on what is acceptable rather than on desirable 
traits.  For instance, which patient populations are in need of a new therapeutic?  Must the drug be 
taken as a tablet, an injection or topical agent?  Similarly, what level of clinical benefit is required to 
replace or supplement the standard of care?  
Initiating a new drug discovery project: finding a starting point
Having defined success criteria with a TPP, the team must then decide where the project will find a 
chemical or biological starting point.  For small molecule drug discovery there are four main options:
1. Screening 
For novel biological targets, where there are no known drugs, the project will need to find a small 
molecule starting point for the project that is called a “hit”.  The most common screening method is 
high throughput screening (HTS).  This involves the testing of thousands to millions of diverse 
chemical compounds either directly against the drug target biochemically (target based screening) or
in a cellular system (phenotypic screening).  Active hits should be carefully assessed to ensure that 
they are true positives.  
The “hit” is then optimised in a phase called Hit to Lead.  An iterative design-make-test approach is 
employed, where the chemical structure is altered to optimise activity, selectivity and physical 
properties.  The resulting “leads” are tested to determine their pharmacokinetic profile and 
tolerability in animals.  If the leads are predicted to be safe and effective, they are then tested in 
animal models of disease.  They may however be evaluated in cellular or ex vivo models when no 
suitable animal model exists.  If a “lead” is active in the animal model and assuming the project has 
not identified other significant issues, it then progresses into a phase called Lead Optimisation (LO).  
In LO, multi-parametric optimisation is conducted to find the optimal balance of properties including 
the drug’s physical characteristics and biological activity as well as the pharmacokinetic and safety 
profile.  Lead optimisation can be a lengthy process that involves large teams of chemists as well as 
expensive assays and experiments, including employing cellular and animal models of drug exposure,
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safety and efficacy.  If successful, LO culminates in the declaration of a preclinical candidate.  At this 
point the molecular structure of the drug is no longer altered: the drug has been discovered.  It will 
then progress through manufacturing process development and regulatory toxicity testing (Pre-
clinical development), to assess safety prior to initiating human trials (Phase 1).
Typically, it is easiest to obtain a patent position in a project that starts from a library screen.  
However, it is the most time consuming, complex and expensive approach to drug development.  It is
important to highlight that historically dermatology has not been the initial focus of drug discovery 
efforts on novel biological targets.  For example, phosphodiesterase 4 (PDE4) (O'Donnell, 2004) and 
(PDE4) Janus kinase (JAK) inhibitors (Hutmacher, 2008) were initially evaluated in clinical trials of 
non-skin diseases, before their use in dermatology was explored.  Screening approaches to drug 
discovery have therefore been comparatively rare in dermatology.  
2. Fast follower
The observation of Nobel laureate Sir James Black that “the most fruitful basis for the discovery of a 
new drug is to start with an old drug” is still true today.  This maxim can be applied to repositioning, 
reformulation and fast-follower approaches to drug discovery, all of which enable researchers to 
deliver effective therapies to patients in the shortest possible time.
The fast follower approach starts with a known drug that is altered with the aim of delivering an 
improved therapeutic profile.  These projects start in the LO phase, skipping the early stages and 
saving time and effort.  Fast followers often aim to deliver improved selectivity and safety profiles.  In
dermatology an oral drug may be re-designed and optimised for use as a topical therapy.  
The JAK inhibitors are promising therapies under investigation for use in dermatology.  Tofacitinib 
was the first JAK inhibitor to be approved (Cotter et al., 2018).  Ruxolitinib and baricitinib, which are 
being evaluated in clinical trials may be considered to be fast followers as they contain many 
structural features present in tofacitinib, Figure 2 (Cotter et al., 2018).  Fast followers will often have 
altered clinical profiles, as even small changes to a drug’s chemical structure can lead to large 
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differences in selectivity or other properties.  This is especially evident when the fast follower is 
designed for use in a new route of administration, for instance, topical vs oral.  
The fast follower approach is well suited to the discovery of topical “soft drugs”.  Soft drugs are stable
and active when locally applied to skin, but on entering the blood are rapidly metabolised.  
Remetinostat is a recently discovered soft-drug topical histone deacetylase (HDAC) inhibitor that 
contains a commonly used HDAC binding motif, but incorporates ester soft drug groups that are 
rapidly metabolised, Figure 2.  In a phase 2 trial for the treatment of mycosis fungoides, 40% of 
patients treated twice-daily with 1% remetinostat gel achieved a confirmed response but lacked the 
side effects associated with systemic HDAC inhibitors (Duvic et al., 2018).
A key benefit of a fast follower approach over re-positioning or re-formulation is that it enables 
composition of matter patents to be filed covering the intellectual property associated with the new 
drug.  This protects the interests of the drug discovery companies or investors who must pay for 
expensive clinical trials.
3. Repositioning
The quickest approach to drug discovery is the repurposing or repositioning of existing drugs
(Michael J. Barratt, 2012).  While only approximately 10 percent of new chemical entity (NCE) 
applications obtain market approval, it is estimated that nearly 30 percent of repurposed drugs do 
so, providing a significant incentive for finding ways to repurpose existing drugs (Kaiser, 2011).
Discovering a new use for an existing drug has some clear advantages.  In general, the safety, efficacy 
and toxicity of the existing drug has been studied extensively.  Repurposed drugs do however require
some exposure to the drug discovery process, to check that the drug is effective in disease relevant 
models of the proposed indication. 
As the chemical structure of the drug is not novel, composition of matter patents are not an option, 
however other approaches to gaining a commercially viable product may be possible such as filing a 
use patent or seeking regulatory protection (Smith, 2011).  
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A fascinating example for dermatology is the repurposing of thalidomide, a drug previously used as a 
sedative that had the adverse effect of causing thousands of birth defects (McBride, 1961). In 1998 
thalidomide was approved as a new treatment for erythema nodosum leprosum, a painful skin 
condition arising in leprosy patients (Teo et al., 2002), Figure 2.  By avoiding treatment of pregnant 
mothers the primary side effect (birth defects) is avoided.  A recent study of the topical 
pharmacokinetics of tofacitinib (Purohit 2019) illustrates a general observation that topical 
application of a drug to BSA of <30% rarely leads to systemic drug concentration sufficient to lead to 
side effects.  Repositioning can therefore be a particularly effective strategy in dermatology.  
4. Reformulation
Reformulation is a subcategory of repositioning that is common in dermatology.  It is often used 
when it is desirable to reposition an existing drug for use in a dermatological condition, but the 
existing drug has been formulated for oral use (Abadir et al., 2018).  It is also used to combine two 
effective agents into one formulation, to simplify treatment regimens or to provide an optimal 
dosage for improved efficacy.  The reformulation of oral drugs for topical use still requires 
development of a safe and patient-friendly formulation and testing in animal models to assess the 
safety and efficacy of the new formulation prior to human clinical trials.  
A recent example of re-formulation is valsartan (Abadir et al., 2018).  Valsartan is an approved 
therapy for the management of blood pressure, Figure 2.  In pre-clinical studies, 1% valsartan gel 
accelerated wound closure in mice and porcine models and the approach may provide a valuable 
new therapy for the treatment of chronic wounds in diabetic patients (Abadir et al., 2018).   
Summary
In the authors’ experience the most effective drug discovery projects involve a wide range of 
stakeholders.  We hope that in this article we have provided an outline of why drug discovery 
matters, what’s involved and how you, the reader, can contribute to the development of meaningful 
new therapies for patients. 
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Questions





2. What is a good approach to finding a hit (chemical starting point) for a novel drug target?





3. What is the primary deliverable of the Lead Optimisation stage of the drug discovery process
A. A lead with activity in animal models
B. A preclinical candidate
C. An approved drug
D. A clinical candidate
4. What is the main weakness in a repositioning project relative to other approaches?
A. It is more expensive
B. It is less likely to succeed
C. Intellectual property protection can be challenging
D. It requires additional technical expertise






1. C: The cost of drug discovery is estimated as being around $1.8 billion.  This cost includes the
cost of failure and accounts for the cost of investing in projects that may take more than a 
decade to deliver a new medicine.
2. A: Unless there are published examples of prototype or approved drugs then the only option 
for a new project is to screen (test) a library of potential drugs to find the starting point (hit) 
for the project.
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3. B: The lead optimisation phase leads to the discovery of a pre-clinical candidate (the 
prospective drug).  The prospective drug is then named a clinical candidate once it has 
passed pre-clinical development.
4. C: Repositioning is an attractive approach but it can be challenging to protect the intellectual 
property, as the drug itself is already known and the use may have been suggested in the 
literature, thus preventing patent protection. 
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Tables
Table 1: FDA drug approvals for dermatology 2014-2018. The table does not include systemic 
treatments for metastatic cancers of skin origin or cancers of skin origin with high metastatic 
potential such as melanoma. Libtayo is approved for locally advanced SCC as well as metastatic SCC 
and is therefore included.
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Table 2: A list of common questions in a TPP
Topics Objectives
Indications Disease of study
Populations Which patient population does the TPP refer to?
Clinical Efficacy
What are the weaknesses in the current treatments? What is required to 
supplant or supplement current treatments?
Safety and 
Tolerability
Are any side effects acceptable? If so, what level of, and what form of, side 
effects would be tolerated in the patient population?
Stability




Which routes of administration are acceptable for the indication/patient 
population? 
Dosing Frequency
How often and how long is treatment acceptable for the patient population, 
when considering requirements for cure or maintenance of disease 
remission?
Cost
What cost would the target patient population (or payer organisation) 
tolerate for a new treatment?
Figure legends
Figure 1: An overview of the drug discovery process.  The numbers (No.) for “Success rate”, “No. 
projects per launch”, “Total cost ($m)” and cost of capital were taken from a well-accepted economic 
model of drug discovery (Paul et al., 2010).“Success rate” refers to the proportion of projects 
successfully progressing to the next stage of development.  The cumulative success rate allows 
calculation of the number (No.) of projects required at each stage, in order to deliver one new drug 
launch, on average: “No. projects per launch”.  “Total cost ($m)” refers to the cumulative cost of all 
projects required at a given stage of development, in order to deliver one drug launch.  The costs 
16
include the cost of capital (11%) that accounts for the lost opportunity cost of developing a drug 
compared with a comparable investment.  
Figure 2: An illustration of the fast follower approach. Many JAK inhibitors contain common features 
(blue), while other elements differ (black) with the aim of delivering an improved therapeutic profile 
for a targeted patient population. Remetinostat contains a common HDAC binding motif (blue) but 
incorporates metabolically labile esters (red).
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Figure 1
Figure 2
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